Table 2 2-year and 5-year melanoma-specific survival and 95% confidence interval (CI) for each stage of the 7th and 8th edition TNM melanoma staging system
Melanoma-specific Survival | ||||||||
|---|---|---|---|---|---|---|---|---|
TNM7 | TNM8 | |||||||
Stage | 2-year | 95% CI | 5-year | 95% CI | 2-year | 95% CI | 5-year | 95% CI |
IA | 99.9% | 99.6–100.0% | 99.4% | 99.0–99.6% | 99.8% | 99.6–99.9% | 99.1% | 98.7–99.3% |
IB | 99.2% | 98.6–99.5% | 97.1% | 96.2–97.8% | 98.5% | 97.4–99.1% | 95.6% | 94.0–96.8% |
IIA | 96.9% | 95.0–98.1% | 90.3% | 87.4–92.6% | 97.1% | 95.2–98.2% | 90.4% | 87.5–92.7% |
IIB | 92.2% | 89.1–94.5% | 81.0% | 76.5–84.6% | 92.2% | 89.0–94.5% | 80.8% | 76.4–84.5% |
IIC | 86.6% | 81.8–90.1% | 69.0% | 62.7–74.4% | 86.6% | 81.8–90.1% | 69.0% | 62.7–74.4% |
IIIA | 94.7% | 90.1–97.2% | 85.0% | 78.6–89.6% | 98.2% | 93.1–99.6% | 91.7% | 84.6–95.6% |
IIIB | 90.8% | 86.0–93.9% | 70.5% | 63.8–76.3% | 90.9% | 84.1–94.8% | 74.8% | 66.0–81.7% |
IIIC | 63.0% | 55.9–69.3% | 45.6% | 38.3–52.5% | 79.1% | 74.2–83.2% | 59.0% | 53.1–64.3% |
IIID | - | - | - | - | 37.4% | 22.3–52.4% | 23.5% | 10.8–39.0% |
IV | 39.0% | 25.7–52.1% | 14.4% | 6.3–25.6% | 39.0% | 25.7–52.1% | 14.4% | 6.3–25.6% |